Showing results (41-50 of 229) with videos related to
Sort By:
Pageof 23
British Journal of Haematology|July 28, 2015
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphomaYasuhiro Oki, Michelle Fanale, Jorge Romaguera, et al.Biointerphases|July 9, 2021
Microscale ZnO with controllable crystal morphology as a platform to study antibacterial action on Staphylococcus aureusJohn M Reeks, Iman Ali, William J Moss, et al.Plant Molecular Biology|June 9, 2018
The bHLH transcription factor ILR3 modulates multiple stress responses in ArabidopsisRozalynne Samira, Baohua Li, Daniel Kliebenstein, et al.Cancer Causes & Control : CCC|March 20, 2019
Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national dataDima Dandachi, Quinn T Ostrom, Insun Chong, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2026
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT TrialJohn P Leonard, Marek Trněný, Huilai Zhang, et al.International Journal of Hematology|November 20, 2022
Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trialNoriko Fukuhara, Koji Kato, Hideki Goto, et al.Human Genetics|December 2, 2025
MutAnt: mutation annotation tool predicts deleteriousness of missense mutations and improves mutation calling from transcriptomicsAleksandr Sarachakov, Anastasiya Yudina, Viktor Svekolkin, et al.Blood|March 13, 2012
The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell linesManuela Lemoine, Enrico Derenzini, Daniela Buglio, et al.Leukemia Research|May 15, 2013
XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cellsBing Z Carter, Duncan H Mak, Zhiqiang Wang, et al.Blood|December 16, 2004
MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cellsLiza Ho, R Eric Davis, Béatrice Conne, et al.Pageof 23